Non-Viral, Large Scale Delivery of Gene Editing Tools for T Cell Manufacturing

Explore non-viral electroporation methods for large-scale T-cell engineering in this 42-minute webinar presented by Andrea Toell, PhD and Stefanie Muethel, PhD. Discover how next-generation electroporation platforms serve as promising alternatives to viral transduction methods, with increasing adoption in clinical trials for cell manufacturing applications. Learn to achieve reliable and efficient delivery of diverse cargo types including DNA, mRNA, CRISPR ribonucleoprotein complexes for knock-out and knock-in applications, and transposon-based integration systems into T-cell populations. Master the scaling process from small laboratory formats to manufacturing volumes of up to one billion T cells while maintaining optimal transfection parameters and cell viability. Examine scientific datasets demonstrating successful adaptation of electroporation protocols for clinically relevant gene editing applications. Understand how modern electroporation platforms support Good Manufacturing Practice (GMP) requirements for therapeutic cell production. Gain insights into the technical considerations for transitioning virus-free cell engineering methods from research to clinical manufacturing scales, with practical guidance on parameter optimization and process validation for large-volume T-cell modification workflows.